Unichem receives ANDA approval for Prasugrel Tablets
Drug Approval

Unichem receives ANDA approval for Prasugrel Tablets

Prasugrel tablets are indicated to reduce the rate of thrombotic CV events

  • By IPP Bureau | August 31, 2023

Unichem Laboratories Limited has received ANDA approval for its Prasugrel Tablets USP, 5 mg and 10 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Effient® (Prasugrel) Tablets, 5 mg and 10 mg, of Cosette Pharmaceuticals, Inc.

Prasugrel tablets are indicated to reduce the rate of thrombotic CV events (including stent thrombosis) in patients with acute coronary syndrome. The product will be commercialized from Unichem's Goa Plant.

Upcoming E-conference

Other Related stories

Startup

Digitization